These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37828105)

  • 1. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
    Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
    Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma.
    Liu Q; Zhu J; Huang Z; Zhang X; Yang J
    Technol Cancer Res Treat; 2024; 23():15330338241239139. PubMed ID: 38613350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wu J; Guo Y; Zuo ZF; Zhu ZW; Han L
    World J Gastroenterol; 2023 May; 29(19):2961-2978. PubMed ID: 37274806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis.
    Ren H; Liu C; Zhang C; Wu H; Zhang J; Wang Z; Chen L; Wang H; Shao C; Zhou L
    Cancer Cell Int; 2024 Mar; 24(1):92. PubMed ID: 38431620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma.
    Ruan J; Xu S; Chen R; Qu W; Li Q; Ye C; Wu W; Jiang Q; Yan F; Shen E; Chu Q; Jia Y; Zhang X; Fu W; Chen J; Timko MP; Zhao P; Fan L; Shen Y
    Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36259363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
    Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
    Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
    Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
    Front Immunol; 2022; 13():943066. PubMed ID: 36159865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
    Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
    Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
    Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
    Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
    Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
    Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.
    Song Y; Zhang Z; Chai Q; Zheng H; Qi Y; Xia G; Yu Z; Yang R; Huang J; Li Y; Peng C; Jiang B; Liu S
    Am J Chin Med; 2023; 51(3):701-721. PubMed ID: 36823098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
    Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
    Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prediction of prognosis of patients with radical resection of intrahepatic cholangiocarcinoma based on single cell omics].
    Chen JL; Tang Y; Qin DL; Li ZL; Tang ZH; Quan ZW
    Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):316-323. PubMed ID: 38432673
    [No Abstract]   [Full Text] [Related]  

  • 16. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
    Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
    BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
    Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
    Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
    Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
    Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.